Trial reportAntimicrobial agents and chemotherapy2007
Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults.
Trial report in Antimicrobial agents and chemotherapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Pharmacokinetic/pharmacodynamics variability of echinocandins in critically ill patients: A systematic review and meta-analysis.Journal of clinical pharmacy and therapeutics · 2020Pooled it
- Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients.Antimicrobial agents and chemotherapy · 2010Trial
- A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.Clinical pharmacokinetics · 2020Article
- Assessment of micafungin loading dosage regimens against Candida spp. in ICU patients by Monte Carlo simulations.European journal of clinical pharmacology · 2020Article
- Micafungin as antifungal prophylaxis in non-transplanted haemotological patients.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2020Observational
- Evaluation of Candida peritonitis with underlying peritoneal fibrosis and efficacy of micafungin in murine models of intra-abdominal candidiasis.Scientific reports · 2019Article
- Clinical and Microbiological Characteristics of Candida guilliermondii and Candida fermentati.Antimicrobial agents and chemotherapy · 2018Article
- Clinical Pharmacokinetics and Pharmacodynamics of Micafungin.Clinical pharmacokinetics · 2018Review
- Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction.European journal of drug metabolism and pharmacokinetics · 2015Article
- Altered Micafungin Pharmacokinetics in Intensive Care Unit Patients.Antimicrobial agents and chemotherapy · 2015Observational
- Bronchopulmonary disposition of micafungin in healthy adult volunteers.Antimicrobial agents and chemotherapy · 2009Article
- Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients.Paediatric drugs · 2009Review
- In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model.Antimicrobial agents and chemotherapy · 2008Article
- Micafungin in the treatment of invasive candidiasis and invasive aspergillosis.Infection and drug resistance · 2008Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We assessed the pharmacokinetics and interactions of steady-state micafungin (Mycamine) or placebo with steady-state voriconazole in 35 volunteers. The 90% confidence intervals around the least-squares mean ratios for micafungin pharmacokinetic parameters and placebo-corrected voriconazole pharmacokinetic parameters were within the 80%-to-125% limits, indicating an absence of drug interaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.